Roche says flexible pricing ready for cancer, not MS drugs

ZURICH (Reuters) - The spotlight on finding a cancer cure has spurred improvements in systems to collect and analyze oncology data, but efforts to track patients with other diseases lag behind, Roche pricing head Jens Grueger said.